Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic revenue guidance has seen the stock clobbered 17% in Copenhagen.
Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up
Related Posts
Popular News
-
Grayscale replaces ADA with BNB in latest GDLC fund rebalance
-
Is Dogecoin Price Preparing 17,000% Pump after Another Elon Musk DOGE Tweet?
-
The 10 best banks for college students in 2025
-
We just got reasons to love these 2 portfolio stocks even more
-
Which Airport Lounges Offer Free Access for Military Members?
Latest News
Mercado Bitcoin Deploys $20M in Private Credit on Rootstock
Latin American digital asset platform Mercado Bitcoin said that it had deployed more than $20 million of tokenized private credit...
LiquidChain touts 1,965% staking rewards for cross-chain Layer 3
LiquidChain launches a Layer 3 cross-chain platform linking Bitcoin, Ethereum, and Solana, advertising 1,965% staking rewards and positioning itself as...
Uber forecasts profit below estimates as cheaper rides boost trips but hurt margins
Uber forecasts profit below estimates as cheaper rides boost trips but hurt margins
Scottish Widows rolls out new LTAFs
Scottish Widows has added two new propositions to its Lifetime Investment range that give workplace pension members exposure to private...
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.